A time travel journey through cancer therapies
Cancer Targeted Drug Delivery: An Elusive Dream, Page: 3-35
2013
- 2Citations
- 4Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Book Chapter Description
The twentieth century was a landmark period in the history of cancer therapies; a time in which conventional cancer treatments such as surgery resection, radiotherapy and chemotherapy made tremendous advances and gave birth to strategies focused on greater selective targeting. Rational drug design allied to rational drug delivery, being led by novel small molecule anti-cancer compounds and monoclonal antibodies. Such approaches prolonged survival time, often without the horrific side effects of previous therapies, but rarely prevented ultimate disease relapse. Selective targeting of membrane transporters and receptors using prodrugs, polymer-cancer drug conjugates and antibody-toxin combinations has contributed to redefine the roadmap of cancer cell targeting. Current pharmacotherapies are still far from consistently delivering cures or sustained remissions. This chapter describes some of the historical events that brought about current cancer targeting strategies.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84929663689&origin=inward; http://dx.doi.org/10.1007/978-1-4614-7876-8_1; https://link.springer.com/10.1007/978-1-4614-7876-8_1; https://dx.doi.org/10.1007/978-1-4614-7876-8_1; https://link.springer.com/chapter/10.1007/978-1-4614-7876-8_1
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know